Allan Elarmo, NP
Family · Moreno Valley, CANPI 1659705689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novo Nordisk at 38.0% of the total. Reporting peaked in 2021 at $140 and has fallen 77.8% since, to $31 in 2024. That places this record below the midpoint for family clinicians in CA, where the typical reported total is $277.
Across 15 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$105
- AbbVie$56
- Shionogi Inc$31
- Astellas Pharma US Inc$28
- Lilly USA, LLC$28
- Baxter Healthcare$27
What the payments were for
- Food & beverage$276100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 6 | $105 |
| AbbVie | 3 | $56 |
| Shionogi Inc | 1 | $31 |
| Astellas Pharma US Inc | 2 | $28 |
| Lilly USA, LLC | 2 | $28 |
| Baxter Healthcare | 1 | $27 |
How this compares
$276 in reported general payments places this provider in the 45th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $28,724 |
| Lacosamide | 30 | $6,578 |
| EntrestoSacubitril/Valsartan | 16 | $5,329 |
| XareltoRivaroxaban | 11 | $2,901 |
| Scopolamine | 19 | $2,050 |
| Permethrin | 28 | $1,549 |
| Atorvastatin Calcium | 175 | $1,459 |
| Gabapentin | 92 | $1,277 |
| Divalproex Sodium | 59 | $1,263 |
| Levothyroxine Sodium | 119 | $1,162 |
| Potassium Chloride | 33 | $1,090 |
| Memantine Hcl | 56 | $1,082 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $928 |
| Diltiazem 12hr ErDiltiazem Hcl | 21 | $896 |
| Solifenacin Succinate | 20 | $755 |
Paid to pharmacies, not to this prescriber.
Other family in Moreno Valley
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.